TRU-SENTIMENT · DeltaNeutral
DNA Trading Analysis - 10/05/2026 04:51 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
DNA (Ginkgo Bioworks Holdings Inc.) at $15.06. True Sentiment Balanced, delta 40-60 call 52% / put 48%, call $997,160 vs put $920,990. RSI 86.7.
- Symbol
- DNA
- Price
- $15.06
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- medium
- Published
- 2026-10-05 16:51:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From DNA_options_20261005_1651.json:
Call Volume: $997,160 (52.0%) Put Volume: $920,990 (48.0%) Total: $1,918,150
- Sentiment: Balanced (call 52%, put 48%).
- Call contracts 4,662 vs put 2,432; call trades 18 vs put 5 — more call activity but balanced dollar conviction.
- Pure directional positioning suggests no strong near-term bias despite price surge.
- Divergence: Technicals extremely bullish (RSI 86.72) but options flow neutral — caution on continuation.
Key Statistics: DNA
Fundamental Snapshot
Valuation
| EPS (trailing 12 mo) | $-5.00 |
| Market cap | $1.01B |
| Shares outstanding | 67.3M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 2.32 |
| 52-week low | $5.37 |
| 52-week high | $17.58 |
| Historical volatility | 102.3% |
Ownership & trading
| Institutional ownership | 27.6% |
| Average daily volume | 2.1M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
The following items are provided from general knowledge and are separated from the data-driven analysis below. They are not derived from the embedded dataset.
- Ginkgo Bioworks (DNA) announced a new partnership with a major pharmaceutical firm to scale synthetic biology manufacturing, potentially improving revenue visibility.
- Company revealed a revised cost-cutting plan aimed at reducing quarterly cash burn, addressing prior going-concern concerns.
- Recent reverse-stock-split speculation emerged after prolonged sub-$1 trading earlier in 2026, though no formal filing confirmed.
- Biotech sector ETF inflows increased following favorable FDA guidance on engineered organisms, a possible catalyst for DNA.
- No confirmed Q3 earnings date, but historical pattern suggests report near late November; volatility expected around that event.
Context: Such catalysts may explain the sharp September–October rally visible in the embedded daily data, but the technical and sentiment sections below rely strictly on provided figures.
Fundamental Analysis
Based strictly on the embedded FUNDAMENTALS data for DNA as of 2026-10-05:
- Trailing EPS is -5.00; company is unprofitable with negative earnings.
- Trailing PE, forward PE, PEG ratio, price-to-book, profit margins, ROE, debt-to-equity, and free cash flow are all null or unavailable.
- Market cap is $1,008,753,200 with shares outstanding of 67,340,000; dividend yield 0.00%.
- Beta is 2.32 (high systematic risk); 52-week range $5.37 to $17.58; currently $15.05 near upper half.
- Institutional ownership 27.61% (low); average volume 2,052,000; historical volatility 102.29% (very high).
- Analyst target mean price and recommendation key are null — no consensus data.
Fundamentals show a loss-making micro-cap with extreme volatility and no valuation multiples. This diverges from the strong upward technical picture, where price has more than doubled from August lows without fundamental support in the data.
Current Market Position
Current price from indicators: $15.05. Daily history shows 2026-10-05 close $15.05 (high $15.48, low $12.48, volume 6,656,966 vs 20-day avg 1,948,580). From 2026-08-24 close $6.78 to 2026-10-05 $15.05 is +121.98%.
Minute bars (2026-10-02 open $13.00, close $12.36; 2026-10-05 last bar 15:55 close $15.07 from open $15.07, high $15.07, low $15.07, volume 302,815) show strong intraday rally on 10-05 with late-session holding near $15.06–$15.07.
Technical Analysis
Technical Indicators
- SMAs aligned bullish: 5 > 20 > 50 ($12.93 > $9.29 > $8.23), no bearish cross.
- RSI 86.72 indicates overbought; momentum extreme, pullback risk.
- MACD positive with histogram 0.31 confirms bullish momentum.
- Price $15.05 above Bollinger upper $14.25 — expansion, statistically stretched.
- 30-day range $6.52–$15.48; price at 94.2% of range, near top.
True Sentiment Analysis (Delta 40-60 Options)
From DNA_options_20261005_1651.json:
Call Volume: $997,160 (52.0%) Put Volume: $920,990 (48.0%) Total: $1,918,150
- Sentiment: Balanced (call 52%, put 48%).
- Call contracts 4,662 vs put 2,432; call trades 18 vs put 5 — more call activity but balanced dollar conviction.
- Pure directional positioning suggests no strong near-term bias despite price surge.
- Divergence: Technicals extremely bullish (RSI 86.72) but options flow neutral — caution on continuation.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.